Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC)

Pancreatic Ductal Adenocarcinoma Clinical Trial

— AIR-PANC  

Official title:

Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC): A Single Centre Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05727319
• Other study ID #: GN21ON523
• Status: Recruiting
• Start date: November 17, 2022
• Est. completion date: May 2024

Study information

• Verified date: February 2023
• Source: NHS Greater Glasgow and Clyde
• Contact: Aileen Duffton
• Phone: 01413017428
• Email: aileen.duffton[@]ggc.scot.nhs.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to determine the feasibility of acquiring serial MRI images for longitudinal analysis in pancreatic ductal adenocarcinoma (PDAC) patients. The main question it aims to answer:

Is it feasible to acquire baseline and repeat MR images in Radiotherapy treatment position?

Description:

PDAC is one of the leading causes of cancer deaths in the UK, with the number of deaths resembling the number of new cases each year. Long term survival is poor, with around 3% of patients alive at 5 years, reducing to 1% at 10 years. Outcomes have shown minor improvement over the past few decades, with little impact in survival being achieved. This is a worldwide problem, with pancreatic cancer being 7th cause of cancer death.

Although progress has been made in terms of assessing the molecular profiling of pancreatic cancer, there has been little progress in some of the clinical aspects e.g. optimal radiological assessment to stratify patients. Currently imaging criteria following neo-adjuvant treatment has been shown to be sub-optimal in accurately defining response to treatment, which may prevent patients from receiving the treatment that gives them the best outcomes. The emerging paradigm in using pre-operative treatment (chemotherapy +/- RT) to improve outcomes for patients is likely to become the standard of care, increasing the need for advanced imaging assessments that accurately stratify patients by enhancing what is currently assessable on morphological images.

Quantified imaging biomarkers (QIMB) and radiomics are a highly promising area of RT research which will enhance the future direction of personalised treatment. Groups have used said research to examine tumour response; predict toxicity; and adapt RT for some anatomical sites. However, this area of research is particularly challenging in the abdomen, where many uncertainties exist, e.g. motion of pancreas and organs at risk; and poor image quality due to motion artefacts on imaging. New promising data is emerging from centres where patients are being treated with MR guided radiotherapy (MRgRT) systems. These include serial image analysis using delta radiomics that can predict early response in tumour; and feasibility of acquiring functional MR throughout treatment that shows apparent diffusion coefficient (ADC) change in tumour and a correlation to response. Very little work has been done to measure ADC changes during RT and this is where potential to adapt RT lies.

Diffusion MRI (dMRI) allows increased monitoring of functional changes during or post RT by providing information on the biological characteristics of tissue. Recent data even shows promise in the correlation of treatment outcome to ADC measured or compared pre and post RT, by correlating change in ADC to pathologic response; as a tool to predict patients likely to have a successful R0 resection; and in predicting patients who will not respond to CRT and may require a different disease management.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: May 2024
• Est. primary completion date: May 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed localised PDAC -as determined by the West of Scotland Hepato-Pancreatobiliary (HPB) MDT

• Scheduled to undergo RT +/- chemotherapy

• 18 years of age or older

• Measurable disease on imaging

• Able to give written informed consent

• Patients willing and able to comply with the protocol for the duration of the study

Exclusion Criteria:

• Distant metastatic disease

• Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating physician.

• History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol

• Major surgery within 28 days prior to trial entry

• Any contraindication to MR

• MRI unsafe implants, ferrous metal in the body, insufficient information on previous surgeries, MRI conditional implants where the conditions cannot be met (e.g. pacemakers).

Related Conditions & MeSH terms

• Pancreatic Ductal Adenocarcinoma

Locations

Country	Name	City	State
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow

Sponsors (1)

Lead Sponsor	Collaborator
NHS Greater Glasgow and Clyde

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Metabolic changes	The proportion of patients with RT induced metabolic changes that are predictive of outcomes in PDAC	18 months
Other	Translational	The proportion of patients where transcriptomic subtypes of pancreatic cancer to baseline dMRI and changes of dMRI post RT as a discovery biomarker analysis of response prediction	18 months
Other	Prognostic tool discernment	The proportion of patients where the systemic metabolic fingerprint of the tumour can be used as a prognostic tool to discern response to radiotherapy	18 months
Other	Characterisation	The proportion of patients where the processing of FFPE tissue samples with the Human Whole Transcrtiptome TempO-seq assay for 10 patients can be successfully collected and analysed	18 months
Primary	Reproduciblity	The proportion of patients who have successfully completed acquisition of a baseline and week 1 repeat scans	18 months
Primary	Volumetric and functional feasibility	The proportion of patients where volumetric and functional measurements are reproducible between baseline and repeat scans	18 months
Primary	Region of interest quantifiability	The proportion of patients where a region of interest can be created and quantified imaging parameters (e.g. ADC) can be extracted on baseline and repeat imaging	18 months
Secondary	Image parameter extraction	The proportion of patients where a region of interest (ROI) can be created and quantified imaging parameters (e.g. ADC) can be extracted on baseline and repeat imaging	18 months
Secondary	Morphological data	The proportion of patients where change in ADC pre and post RT correlate to RECIST from SOC to follow up	18 months
Secondary	Reproducibility of motion corrected/gated image acquisition	The proportion of patients where key features can be tested on larger data sets	18 months